I read with great interest the recent article by Joseph et al, 1 which is appearing in this print issue of your esteemed journal. The article is highly thought provoking. Interestingly, the past few years have seen the emergence of gene therapy as a highly effective therapeutic modality for the treatment of tendinopathies.
For instance, PDGF delivered by MCM-41 mesoporous silica nanoparticles (MSN) to injured tendons greatly enhances and fastens the healing process. 2 Similarly, healing in Achilles tendinopathy is significantly increased and enhanced after bone-marrow-derived mesenchymal stem-cell grafts transduced with adenovirus-carrying human TGFbeta1 cDNA. 3 The remodeling of collagen matrix in the injured tendons is greatly enhanced after bone-marrow-derived mesenchymal stem-cell grafts. Similarly, the fiber bundles are much larger in the treated Achilles tendons. 4 Similarly, Rickert et al 5 recently demonstrated the use of adenoviruses to deliver the growth and differentiation factor-5 gene to injured Achilles tendons. This results in increased collagen type II synthesis and accelerated healing. In vivo, the growth and differentiation factor-5 gene expression is maximal a month after initiating therapy. Similarly, animal models with Achilles tendinopathy demonstrate accentuated tensile strength after BMP-14 gene therapy, 6 and exogenous vascular endothelial growth factor therapy significantly improves tensile strength in Achilles tendinopathy. 7 Clearly, gene therapy provides for a unique and promising way to treat Achilles tendinopathy. I hope that the coming few years will see more studies to further assess its safety and effectiveness.
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